Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-BR-1-GM and Pembrolizumab in Solid Tumors With CNS Metastases
NCT07199413Phase 1Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2026
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label, single-arm trial of SV-BR-1-GM in brain metastases and leptomeningeal metastasis (LM), sponsored by Medical College of Wisconsin. Primary endpoints: Grade 3 or higher adverse events at 9 months and Study therapy duration at 6 months. Planned start Jun 2026; status: withdrawn.
02
Drugs
SV-BR-1-GM
03
Conditions
brain metastasesleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT07199413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199413.